No black box warning on record for Imdelltra (amg757)

As of the latest FDA labeling reviewed, Imdelltra (amg757) (TARLATAMAB-DLLE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Imdelltra (amg757) medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cytopenias : Monitor complete blood counts prior to administration of all doses of IMDELLTRA up through Cycle 5 Day 15 and then prior to administration of IMDELLTRA on Day 1 of each cycle starting with Cycle 6. More frequent evaluation may be necessary as clinically indicated. Withhold or permanently discontinue based on severity. ( 5.3 ) Infections : Monitor for signs a

No black box warning on record for Imdelltra (amg757)

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cytopenias : Monitor complete blood counts prior to administration of all doses of IMDELLTRA up through Cycle 5 Day 15 and then prior to administration of IMDELLTRA on Day 1 of each cycle starting with Cycle 6. More frequent evaluation may be necessary as clinically indicated. Withhold or permanently discontinue based on severity. ( 5.3 ) Infections : Monitor for signs a

Imdelltra (amg757) Black Box Warning

No black box warning on record for Imdelltra (amg757)

Other warnings & precautions

Imdelltra (amg757) Black Box Warning

No black box warning on record for Imdelltra (amg757)

Other warnings & precautions